Centre National De La Recherche Scientifique

Universitè De Montpellier

Bio-rad Europe Gmbh

Alcediag

Chu Monpellier

Bio-rad Innovations

Chu Montpellier

Nicolas Salvetat

Dinah Weissmann

Franck Molina

Claude Granier

Berengere Vire

Siem Van Der Laan

Laurence Molina

Randa Siala

Eric Renard

Fabrice Chimienti

The present invention is drawn to a method for in vitro predicting the risk for a patient to present a pathology or to identify whether a patient is at risk to develop a pathology, such as psychiatric disorder, associated to an alteration of A-to-I editing on PDE8A transcripts, from body fluids such as a blood, urine or saliva sample of said patient. The present invention also relates to kits for the implementation of the method.

RNA editing as biomarkers for mood disorders test

The present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy. Finally, the invention concerns a kit comprising means for detecting at least two proteins selected from the group consisting of heparan sulfate proteoglycan core protein or fragments thereof, carbonic anhydrase 1, prothrombin or fragments thereof, tetranectin, CD59 glycoprotein, plasma serine protease inhibitor, mannan-binding lectin serine protease 2 or isoforms thereof, antithrombin-III, alpha-1-antitrypsin, collagen alpha-1(I) chain, alpha-enolase, histone H2B type 1-O, glutaminyl-peptide cyclotransferase, protein AMBP and zinc-alpha-2-glycoprotein.

Early prediction markers of diabetic nephropathy

Growing community of inventors

Montpellier, France

Nicolas Salvetat